bullish

Polaris Group

Polaris Group (6550 TT): An Attractive Bet With Differentiated Approach To Cancer Therapy

Tina has highlighted this Insight as a Top Pick
325 Views04 Sep 2022 18:37
Polaris’ lead candidate, ADI-PEG 20 is in late-stage trial for various cancers. Topline data from phase 2/3 trial for mesothelioma is expected this month. Polaris expects 2 new drug approvals by 2025.
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Rising
Tina Banerjee
Global Healthcare Analyst
Health CareEquity Bottom-UpThematic (Sector/Industry)
Price Chart(Sign Up to Access)
analytics-chart
x